Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Initially considered a curable disease due to substantial sensitivity to chemotherapy, small cell lung cancer (SCLC) remains a fatal disease with a poor outcome, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of numerous targeted therapies, the field of SCLC has seen little advancement, and the standard of care (SOC) for several decades has been platinum-etoposide chemotherapy. Limited tumor tissue for translational research, poor understanding of the mechanisms underlying disease biology, and therapeutic resistance are major factors impeding the discovery of effective drugs, including targeted therapies in SCLC, proving a major clinical need for patients.
To date, there have been three targeted therapies approved to treat SCLC, Bristol-Myers Squibb’s Opdivo (nivolumab), Roche’s Tecentriq (atezolizumab), and Merck & Co.’s Keytruda (pembrolizumab) which were approved by the FDA in August 2018, March 2019 and June 2019, respectively. The recent approval of targeted and immuno-therapies for SCLC will generate a new maintenance setting following chemotherapy in SCLC. Following the approval of these new agents, relapsed/refractory patients are expected to have significantly improved therapeutic options. The increased prescription of branded therapies in treatment-naïve and advanced patients will be the primary impetus driving the substantial growth in the SCLC market.

Scope

There are 165 pipeline programs in active development for SCLC. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?

Which molecular target classes are prominently represented in the first-in-class SCLC pipeline? Which first-in-class targets have been identified as most promising for the treatment of SCLC? How does the distribution of target classes differ in terms of development stage?

Across the SCLC landscape, there are 118 active companies. Which companies have formed partnerships? Which companies have first-in-class assets in development with no prior deal involvement?

Reasons to Buy

Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology. Visualize the composition of the SCLC market in terms of dominant molecule types and molecular targets.

Analyze and compare the SCLC pipeline and stratify by stage of development, molecule type, and molecular target.

Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class programs have been assessed and ranked according to their clinical potential. Promising first-in-class targets have been reviewed in greater detail.

Recognize commercial opportunities by identifying first-in-class pipeline programs for SCLC that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class SCLC programs.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Small Cell Lung Cancer: Executive Summary

2.1 Pipeline Holds Some Potential for the Approval of More Targeted Therapies

2.2 High Levels of First-in-Class Innovation

2.3 Need for Disease-Modifying Pharmacotherapies

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.2 Classification or Staging Systems

4.3 Sustained Innovation in SCLC

4.4 Epidemiology for SCLC

4.5 Overview for Marketed Products

5 Assessment of Pipeline Product Innovation

5.1 Overview

5.2 Pipeline by Stage of Development and Molecule Type

5.3 Pipeline by Molecular Target

5.4 Comparative Distribution of Programs Between SCLC Market and Pipeline by Therapeutic Target Family

5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class

5.5.1 Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Programs

5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets Within the Pipeline

6 First-in-Class Molecular Target Evaluation

6.1 Overview

6.2 Pipeline Programs Targeting GTPase KRAS

6.3 Pipeline Programs Targeting Interleukin 2 Receptor Beta and Gamma

6.4 Pipeline Programs Targeting Heat Shock Protein 90

6.5 Pipeline Programs Targeting Serine/Threonine Protein Kinase AKT (AKT1, AKT2, AKT3)

6.6 Pipeline Programs Targeting Hepatitis A Virus Cellular Receptor 2

6.7 Pipeline Programs Targeting Serine/Threonine-Protein Kinase ATR

6.8 Pipeline Programs Targeting Protein Phosphatase 2A

6.9 Pipeline Programs Targeting Histone-lysine N-methyltransferase EZH2

6.10 Pipeline Programs Targeting Lymphocyte Activation Gene 3 Protein

7 Key Players and Deals

7.1 Overview

7.1.1 Allogene Therapeutics Enters into Licensing Agreement with Cellectis

7.1.2 Amgen and MD Anderson Enter Two Collaboration Agreements Across Various Cancer Types

7.1.3 MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center

8 Appendix

8.1 Bibliography

8.2 Abbreviations

8.3 Methodology

8.3.1 Market Analysis

8.3.2 Overall Pipeline Analysis

8.3.3 First-in-Class Pipeline Analysis

8.3.4 First-in-Class Matrix Assessment

8.3.5 First-in-Class Molecular Target Evaluation

8.3.6 Key Players and Deals

8.4 About the Authors

8.4.1 Analyst

8.4.2 Therapy Area Director

8.4.3 Global Director of Therapy Analysis and Epidemiology

8.4.4 Global Head and EVP of Healthcare Operations and Strategy

8.5 About GlobalData

8.6 Contact Us

8.7 Disclaimer

Table

Table 1: Definitions Used in TNM Classification and Clinical Staging System in Lung Cancer

Table 2: AJCC Staging of Lung Cancer

Table 3: SCLC Diagnosed Prevalent Cases (N), Thousands, 20142024

Figures

Figure 1: SCLC, Global Market by Molecular Target and Molecule Type, 2019

Figure 2: SCLC, Global, Pipeline by Stage of Development and Molecule Type, 2019

Figure 3: SCLC, Global, Pipeline by Molecular Target and Stage of Development, 2019

Figure 4: SCLC, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2019

Figure 5: SCLC, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2019

Figure 6: SCLC, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2019

Figure 7: SCLC, Global, Ratio of First-in-Class and Non-First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2019

Frequently asked questions

Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease in real time.

  • Access a live Small Cell Lung Cancer – Diverse First-In-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.